title: Synergistic neutralization of simian-human immunodeficiency virus SHIV-vpu+ by triple and quadruple combinations of human monoclonal antibodies and high-titer anti-human immunodeficiency virus type 1 immunoglobulins.
abstract: We have tested triple and quadruple combinations of human monoclonal antibodies (MAbs), which are directed against various epitopes on human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins, and a high-titer anti-HIV-1 human immunoglobulin (HIVIG) preparation for their abilities to neutralize a chimeric simian-human immunodeficiency virus (SHIV-vpu+). This virus encodes the HIV-1 strain IIIB env, tat, rev, and vpu genes. The quantitative nature of the Chou-Talalay method (Adv. Enzyme Regul. 22:27-55, 1984) allows ranking of various combinations under identical experimental conditions. Of all triple combinations tested, the most potent neutralization was seen with MAbs 694/98D plus 2F5 plus 2G12 (directed against domains on V3, gp41, and gp120, respectively) as measured by the total MAb concentration required to reach 90% neutralization (90% effective concentration [EC90], 2.0 microg/ml). All triple combinations involving MAbs and/or HIVIG that were tested yielded synergy with combination index values of < 1; the dose reduction indices (DRIs) ranged from 3.1 to 26.2 at 90% neutralization. When four MAbs (the previous three plus MAb F105, directed against the CD4 binding site) were combined, higher neutralization potency (EC90 1.8 microg/ml) and a higher degree of synergy compared to any triple combination were seen. The mean DRIs of the quadruple combination were approximately twice that of the most synergistic triple combination. We conclude that human MAbs targeting different HIV-1 envelope glycoprotein epitopes exhibit strong synergy when used in combination, a fact that could be exploited clinically for passive immunoprophylaxis against HIV-1.
authors.affiliation: Laboratory of Viral Pathogenesis, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: A
authors.initials: A
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Katinger
authors.forename: M R
authors.initials: MR
authors.lastname: Posner
authors.forename: L
authors.initials: L
authors.lastname: Cavacini
authors.forename: S
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: M K
authors.initials: MK
authors.lastname: Gorny
authors.forename: J
authors.initials: J
authors.lastname: Sodroski
authors.forename: T C
authors.initials: TC
authors.lastname: Chou
authors.forename: T W
authors.initials: TW
authors.lastname: Baba
authors.forename: R M
authors.initials: RM
authors.lastname: Ruprecht
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D002461:Cell Line, Transformed; D004357:Drug Synergism; D015483:HIV Antibodies / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000166:cytology; D008253:Macaca mulatta; D009500:Neutralization Tests; D016865:Reassortant Viruses / Q000276:immunology*; D015302:Simian Immunodeficiency Virus / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; C084715:HIV hyperimmune globulin; D016756:Immunoglobulins, Intravenous